What is the purpose of issuing these new notes?

The 8-K filing does not explicitly state the specific use of proceeds, but debt issuances of this nature are typically for general corporate purposes, which can include funding operations, research and development, potential acquisitions, or refinancing existing debt.

Are these notes guaranteed by any subsidiaries?

No, the filing indicates that the Notes will be effectively subordinated to all obligations of Amgen's subsidiaries. This means that in the event of a subsidiary's financial distress or bankruptcy, the subsidiary's creditors would have a claim on the subsidiary's assets before Amgen could access those assets.

What happens if there's a change in control at Amgen?

If a change in control triggering event occurs, as defined in the Officers' Certificate, holders of these notes may have the right to require Amgen to purchase all or a portion of their notes for cash. The purchase price would be 101% of the principal amount, plus any accrued and unpaid interest.

Can these notes be offered or sold within the United States?

No, the notes have not been and will not be registered under the U.S. Securities Act of 1933. They were sold outside the United States in reliance on Regulation S and may not be offered or sold within the United States.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) filed an 8-K on September 13, 2012, to report on a significant debt financing transaction. The company successfully issued and sold €675 million of 2.125% Senior Notes due 2019 and £700 million of 4.000% Senior Notes due 2029. These notes were offered and sold outside the United States under Regulation S and are not registered for sale within the U.S. The net proceeds from this offering, after deducting discounts and expenses, are approximately €669 million for the 2019 Notes and £685 million for the 2029 Notes. This transaction provides Amgen with substantial capital, likely for general corporate purposes, potential acquisitions, or further research and development initiatives. Investors should note that these senior notes are unsecured and rank equally with other existing and future senior unsecured debt, but are effectively subordinated to obligations of Amgen's subsidiaries and senior to any subordinated debt.

Key Highlights

1Amgen Inc. issued €675 million in 2.125% Senior Notes due 2019.
2Amgen Inc. issued £700 million in 4.000% Senior Notes due 2029.
3The notes were sold outside the United States under Regulation S.
4The notes are unsecured and rank pari passu with other senior unsecured debt.
5Proceeds from the offering are expected to be used for general corporate purposes.
6A change in control triggering event could require Amgen to repurchase the notes at 101% of face value plus accrued interest.

AMGEN INC 8-K Report, Material Agreement (Sep 13, 2012)

Summary

Key Highlights

Frequently Asked Questions